AllSight
Companies · AXGN · Electromedical & Electrotherapeutic Apparatus

Axogen, Inc. (AXGN)

Axogen, Inc. (AXGN) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Axogen, Inc. (AXGN) stock — financials & valuation

Key numbers for Axogen, Inc. (AXGN): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 44/100 — a percentile rank of Axogen, Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.

Market cap$2.5B
P / S9.8×
EV / EBITDA-396.3×
Gross margin74.6%
Operating margin-5.1%
Net margin-13.4%
Return on equity-13.1%
ROIC-7.9%
Revenue growth23.6%
Debt / equity0.0×
Dividend yield0.0%

Is Axogen, Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Axogen, Inc.’s own financial statements and shown as context, never as advice.

Oct 1, 2026BioCircuit acquired
Axogen completes BioCircuit acquisition, adding NerveTape revenue beyond 2026 guidance
Sep 10, 2026$200M acquisition
Axogen buys BioCircuit for $200M, but equity financing raises dilution stakes
Related companies in Electromedical & Electrotherapeutic Apparatus
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact